Information Provided By: 
Fly News Breaks for December 29, 2015
CMRX, ATRA
Dec 29, 2015 | 08:22 EDT
Canaccord noted Chimerix (CMRX) announced disappointing Phase 3 CMV data, which would have reduced the market for Atara (ATRA) if it had been positive. Given the negative results, Canaccord views the failure as an incremental positive for Atara and thus reiterated its Buy rating and $47 price target on Atara shares.
News For ATRA;CMRX From the Last 2 Days
There are no results for your query ATRA;CMRX
